FRANKLIN LAKES, N.J.,
March 14, 2012 /PRNewswire/
-- The final results of the Additional KIF6 Risk Offers Better
Adherence to Statins (AKROBATS) study will be presented at the
American College of Cardiology's 61st Annual Scientific Session
& Expo being held March 24-27,
2012, in Chicago, IL. The
AKROBATS study is a collaborative effort between the Medco Research
Institute™, a subsidiary of Medco Health Solutions, Inc. (NYSE:
MHS) and Quest Diagnostics (NYSE: DGX), the world's leading
diagnostic testing company.
(Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO
)
Presentation Details
Session Number: 1258
Session Type: ACC Moderated Poster Contributions
Session Start/End Time: Monday, Mar 26,
2012, 9:30 AM -10:30 AM
Location: McCormick Place South, Hall A
Presentation Number: 1258-376
Abstract Title: Patient knowledge of pharmacogenetic information
improves adherence to statin therapy: Results of the Additional
KIF6 Risk Offers Better Adherence to Statins (AKROBATS)
trial.
Presenter: Scott L.
Charland, Pharm.D., Medco Research Institute
About AKROBATS
AKROBATS is prospective, nonrandomized intervention trial of the
effect of KIF6 testing results reported directly to the
patient on statin adherence and persistence over six months.
All eligible intervention and control patients were greater than or
equal to 18 years old, new to statin therapy (none 6 months prior),
and from the same sponsored plans (which had granted permission for
their members to participate in the study). Genetic testing for a
common single nucleotide polymorphism (rs20455) resulting in an arginine to tryptophan
substitution at position 719 (Trp719Arg) in the kinesin-like
protein 6 gene (KIF6) was conducted and written results
returned to the patient within 30 days of initiating statin
therapy, and before the first statin prescription
refill. Tested patients were matched to concurrent,
non-tested control patients on age, gender, statin prescription
distribution channel, and the number of chronic medications at time
of statin initiation. The primary endpoint was statin adherence
(proportion of days covered; PDC) at six months. Secondary
end points included achievement of adherence (PDC greater than or
equal to 0.80) and persistence to statin therapy at six
months. AKROBATS is registered on www.clinicaltrials.gov
(NCT01068834).
About Medco Research Institute
Medco Research Institute® is an evidence-based research
organization focused solely on novel research, analytics and new
discoveries that close the gap between scientific discovery and
medical practice for improved patient outcomes and lower overall
healthcare costs. More information about the Medco Research
Institute's peer-reviewed research can be found at
www.medcoresearch.com.
About Medco
Medco Health Solutions, Inc. (NYSE: MHS) is pioneering The
world's most advanced pharmacy® and its clinical
research and innovations are part of Medco making medicine
smarter™ for millions of Americans.
With more than 20,000 employees worldwide dedicated to improving
patient health and reducing costs for a wide range of public and
private sector clients, and 2011 revenue of $70 billion, Medco ranks 34th on the 2011
Fortune 500 list and is named among the world's most
innovative, most admired and most trustworthy companies.
For more information, go to http://www.medcohealth.com.
About Quest Diagnostics and Berkeley HeartLab
Quest Diagnostics, the world's leading diagnostic testing
company, offers genetic and non-genetic testing through Berkeley
HeartLab, the company's business unit specializing in advanced
cardiovascular disease testing. Berkeley HeartLab offers the
4myheart program, an educational program for patients that provides
personalized care, including for medication adherence, to help
patients improve their cardiac health. Quest Diagnostics offers a
laboratory-developed test for the KIF6 gene variant through
Berkeley HeartLab. For more information, visit
www.QuestDiagnostics.com or www.4myheart.com.
This press release contains "forward-looking statements" as that
term is defined in the Private Securities Litigation Reform Act of
1995. These statements involve risks and uncertainties that may
cause results to differ materially from those set forth in the
statements. No forward-looking statement can be guaranteed, and
actual results may differ materially from those projected. We
undertake no obligation to publicly update any forward-looking
statement, whether as a result of new information, future events,
or otherwise. Forward-looking statements in this press release
should be evaluated together with the risks and uncertainties that
affect our business, particularly those mentioned in the Risk
Factors section of the Company's Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q filed with the Securities and
Exchange Commission.
SOURCE Medco Health Solutions, Inc.